BGPartner advises Forbion, Novo Holdings and HBM Healthcare Investments on Series C Top-up financing of Numab Therapeutics Ltd to CHF 180 mio.

Numab Therapeutics Ltd, a Swiss clinical-stage biotech company advancing a proprietary pipeline of multi-specific antibodies in inflammation and oncology, has successfully closed a Series C Top-up financing, raising an additional CHF 50 mio. This increases the total funding for this round to a remarkable CHF 180 mio. 

This financing was made possible through additional investments from Forbion, Novo Holdings, HBM Healthcare Investments and Cormorant Asset Management as co-lead investors. Other existing investors such as BVF Partners L.P., Octagon Capital Advisors LP, RTW Investments, and funds and accounts managed by BlackRock joined the round.

BGPartner advised Forbion, Novo Holdings and HBM Healthcare Investments on all Swiss legal matters and the negotiations of this Series C Top-up, the initial Series C round and the Series C Extension. The team consisted of Oliver Gnehm (Partner), Victoria Marty (Senior Associate) and Tessa Douma (Associate).